Journal of Pharmacy Practice and Pharmaceutical Sciences

Research Article

A Study Showcasing Crystal Medley of Metformin Free Base: Virtual and Experimental Insights

Janhvi Dureja, Renu Chadha*, Maninder Karan, Akshita Jindal and Kunal Chadha

UIPS, Punjab University, Chandigarh, India

Received: 04 December 2018

Accepted: 27 December 2018

Version of Record Online: 31 January 2019

Citation:

Dureja J, Chadha R, Karan M, Jindal A, Chadha K (2018) A Study Showcasing Crystal Medley of Metformin Free Base: Virtual and Experimental Insights. J Pharm Pract Pharm Sci 2018(1): 01-20.

Correspondence should be addressed to

Renu Chadha, India

E-mail: renukchadha@rediffmail.com

DOI: https://doi.org/10.33513/PPPS/1801-07

Copyright

Copyright © 2018 Renu Chadha et al. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and work is properly cited.


Abstract

Objective: The present work reports the existence of polymorphism in metformin free base applying virtual and experimental approach.

Methods: The experimental screening of various polymorphs of metformin free base has been coupled with virtual approach resulting in isolation of three distinct crystal phases from different solvents/ or solvent mixtures. The virtual screening of polymorphs was performed using Polymorph Predictor module of BIOVIA Material Studio (MS) software. A state-of-the-art approach was undertaken utilizing integrated molecular modeling and Monte Carlo simulation technology. The sophisticated tools were used to characterize the experimentally isolated forms such as Differential Scanning Calorimetry (DSC), Fourier Transform Infra-Red Spectroscopy (FTIR), Powder X Ray Diffraction (PXRD) and optical microscopy. Lattice energy landscape was examined to look for these observed forms. Crystal morphology study was conducted to analyse Morphologically Important (MI) facets.

Results: A list of potential polymorphs of the drug molecule was generated with varied lattice constants using MS. Crystal energy landscape obtained from the study provided systematic energy ranking to the polymorphs. DSC of these forms exhibited endothermic peaks at 134.01, 111.24 and 79.84°C respectively indicating them to be different forms of metformin base. Structure determination from powder patterns showed that although all the forms, form I, II and III crystallize out in same triclinic space group, P-1 but they possessed different crystallographic parameters and hydrogen bonding patterns. The predicted results were quite complacent with experimental observations with respect to lattice parameters. The three observed forms have been found as local minima in the lattice energy landscape of potential polymorphs.

Conclusion: The study explained the practical relevance of Crystal Structure Prediction (CSP) in studying the potential polymorphs of a drug molecule by successfully predicting various polymorphs of metformin free base. Out of all predicted polymorphs, three polymorphs were actually isolated experimentally. The information generated about the existence of multiple forms of metformin free base provides an opportunity to select and scale-up the desired crystal form well suited on bioavailability and stability grounds. The process can be escalated further to preclinical study, to emerge as an invaluable technology in future in increasing the efficiency of drug development process.

Keywords:

Crystal Morphology; Crystal Structure Prediction (CSP); Lattice Energy Landscape; Metformin Free Base; Polymorphism; Powder X-Ray Diffraction (PXRD)

Introduction

Multifariousness in crystal forms of a drug molecule has become interesting topic of discussion in the field of pharmaceuticals. This inherent tendency of the compounds to exist in various crystal forms is called polymorphism. In general polymorphism is classified into two major types, viz., monotropism and enantiotropism. This general behavior is based on their temperature linked stability. In the monotropic system, only one polymorph is stable below the melting point of the drug substance and in enantiotropic system, the substance exists in different crystal forms which are interconvertible based on their transition temperature (the temperature at which two polymorphic forms exhibit same free energy). Besides this polymorphism can be categorized into two types based on their arrangements in solid state, i.e., packing polymorphism and conformational polymorphism. In the former the differences are due to molecular packing in the unit cell and in the later case, the substances differ due to the presence of different conformers in their solid-state arrangements. Moreover, literature is flooded with reports and reviews on this interesting phenomenon of polymorphism [1-12]. From regulatory perspectives, a new polymorphic form is designated as a “pharmaceutical alternative” to the original form. Exploring various polymorphic forms of a drug molecule has become a critical part of research and development as phase transformations have a major impact on product quality and stability [1]. It is also quite useful from intellectual proprietary benefits for the pharmaceutical industry [3,4]. It is very well stated that different solid forms of a drug substance exhibit different physicochemical and biopharmaceutical properties such as solubility, dissolution, stability, manufacturability including flowability, tablet compaction, hygroscopicity, etc. This will ultimately affect the bioavailability and bioequivalence of that substance. Furthermore, different solid forms of the active pharmaceutical ingredients can possess variable organoleptic properties such as taste, color etc., [5-11]. Thus, in-depth knowledge of all the crystal forms should be acquired in advance in order to ensure the efficient and successful development of a robust product [12]. The present study focuses on the screening of various crystal forms of metformin free base. Metformin hydrochloride is a first line treatment of Type 2 diabetes [13]. Additionally, modern metformin has received a new attention due to its anti-ageing properties by dramatically increasing the health span of individuals making people healthy, active and alert years longer. This miracle pill favorably modulates the major biological outcomes associated with longevity such as inflammation, stress defence, cellular survival, autophagy and protein synthesis [14-16]. It has countless of other health benefits such as improvement of cognitive function, cardio-protection, anticancer properties, etc., [17]. The present study thus selected this important molecule to play with its solid-state properties. The study focuses on the virtual and experimental screening of various crystal forms of metformin free base. Metformin is a strong base and belongs to BCS class III drug category [17] and is commercialized in its hydrochloride salt form. Unfortunately, its unpleasant taste and high dosing requirements could lead to compliance problems. Moreover, hydrochloride salts could present problems in handling especially in high humidity conditions and has high compaction susceptibility. This salt during manufacturing also generates corrosive action on tablet tooling [18-25]. Furthermore, controlled release formulation of this salt form is difficult to prepare due to its very high aqueous solubility parameter [26]. Thus, in order to deal with the disadvantages of most frequently used hydrochloride salt form of drug, the present work was initiated to explore the various polymorphs of metformin free base with the aim of selection of suitable crystal form for future development. The literature survey has revealed that not much work has been done on polymorphic concepts of metformin free base. The present study is a well-designed screening strategy which is focused on development timelines for the product in pharmaceutical sector. Biovia Material Studio in silico strategy involving Crystal Structure Prediction (CSP) is combined with experimental screening of polymorphic forms. All the observed forms were characterized using sophisticated analytical techniques. The approach followed in the present work is quite efficient in detecting and interpreting various crystal forms of metformin base. The Crystal Structure Determination (CSD) using powder X-ray diffraction scans of various observed forms is then undertaken using Biovia Material Studio. The final outcome of CSP, crystal energy landscape is looked upon for the experimentally observed crystal forms. This gives the idea about the lattice energy associated with these forms which in turn expresses the stability of these solid forms. Furthermore, morphology simulation of observed forms of metformin free base was performed. The final outcome, crystal habit generated from morphology study has assisted CSP in controlling the existence of various polymorphs of drug substance.

Methods

Virtual screening of polymorphs

The Crystal Structure Prediction (CSP) was implemented using Polymorph module of Biovia Material Studio (MS) software suite, version 7.0. The initial step of energy minimization involves geometry optimization using Dmol3 program and COMPASS forcefield technology of MS based on quantum mechanical methods, starting from the input molecular structure of metformin. It creates an optimized input structure for polymorph prediction. The hunt for the polymorphs was executed within most commonly occurring space groups i.e., P-1, Pbca, P21/c, P212121, P2/c, C2/c and P21 [27] and was repeated thrice till all predicted crystal structures converges to equal energy minima. The Monte Carlo method of MS involves a systematic and stepwise approach towards polymorph prediction involving various steps such as packing, pre-clustering, optimization and clustering. The eventual outcome of polymorph prediction is crystal lattice energy landscape (energy versus density plot). It ranks the crystal structures based upon their lattice energy and density parameters and generates a list of lattice parameters of predicted structures within selected space groups [28-30]. This is further looked up for local minima (metastable crystal structures), global minima and thermodynamically most stable form.

Experimental screening of polymorphs

Metformin free base was isolated from commercial sample of Metformin HCl (procured from Thermo Fischer Scientific) as stated in United States patent US 6,031,004 and US 8,076,377 [25,26]. This free base form of metformin was further explored for its polymorphic tendency and success was achieved with slow evaporation method. Different solid forms were successfully isolated by slow evaporation technique using various solvents/ or solvent mixture. The saturated solutions of metformin base in various solvents and solvent mixtures were heated below the boiling point of these solvent/ or solvent mixtures and then kept for evaporation at room temperature. Form I crystallized out from benzaldehyde in 9 days. Form II from 2-propanol appeared in 2 days and form III crystallized out from a solvent mixture of cyclohexane and toluene in 21 days. Crystals observed were filtered and stored in desiccator under controlled humid conditions till further characterization.

Characterization of polymorphs

Thermal analysis: DSC thermograms of isolated forms were interpreted using Q20 DSC instrument by placing the sample (3-5 mg) into sealed aluminium pans and scanning (50- 300°; 10°C/min.; nitrogen purge of 50 mL/min.) Data was interpreted using Universal analysis 2000 software (TA Q series advantage software).

Fourier Transform Infra-Red Spectroscopy (FTIR): The spectral data of the observed forms of metformin free base pressed into pellet (containing 2- 4 mg sample dispersed in approx. 20 mg KBr) was collected over the range of 450- 4000cm-1 using Perkin-Elmer RX-1 FTIR spectrophotometer (UK). For metformin, the free base spectra exhibited a notable band at 1670 cm-1 (C=N imine stretch).

Powder X- Ray Diffraction (PXRD): The samples of all the collected forms (about 200 mg each) were loaded on X′PERT-PRO diffractometer using Cu- Kα radiation (1.54°C) and scanned at 2θ values ranging from 3.5° to 49° with a step size of 0.0170°, scan step time set to 25.1996 s and slit size adjusted to 0.48°C. The diffractograms were recorded and analyzed using XPERT high score software.

Optical Microscopy: The overall macroscopic crystal habit of the different polymorphs was studied by observing optical micrographs of all the samples taken using a Leica DM3000 upright optical microscope with polarizer at an image resolution of 25X.

Crystal structure determination

This was done by collecting the PXRD patterns of observed forms and subjecting them to Reflex Plus module of Material Studio. It was performed following four basic steps i.e., indexing, Pawley fitting/ refinement, structure solution and Rietveld refinement [31]. X-cell (Newmann, 2003) indexing program was used for peak indexing to obtain various solutions of crystal lattices. The unit cell possessing highest Figure of Merit (FOM) was then subjected to refinement for attaining accurate lattice constants and lattice parameters. The optimization of unit cell was done from 10 cycles followed with a search for space groups. The optimized molecular structure was imported into the refined empty unit cell. The structure solution was finally carried out by exposing this whole assembly to Powder Solve program of Reflex Plus module of MS [31,32]. Rietveld refinement of the solved structure was executed to generate Rwp (weighted Rietveld parameter) values which further confirms the similarity between a simulated and an experimental diffraction pattern. The final optimization of the structure was achieved using Forcite module of MS.

Crystal morphology simulation

The morphology prediction of the observed polymorphic modifications of was carried out using the Morphology module of MS [33,34]. The maximum h,k,l values (Miller indices) for the faces were set to 5 each with an upper limit of 100 growing faces. The minimum inter- planar spacing (dhkl) for face list generation was adjusted to 1.0 A°. Growth morphology algorithm working on the hypothesis that crystal face growth rate is proportional to its attachment energy [35-37] was then applied to observed crystal structures. The outcome generated is a list of growth faces along with their attachment energy (Eatt). The habit properties including aspect ratio was calculated.

Solubility study

The equilibrium solubility study of observed forms of metformin free base was carried out by shaking an excess of drug (approx. 20 mg) in 10 ml of distilled water using MSW-275 (Macro scientifc works, New Delhi) water bath shaker preset at 37°C and 200 rpm for 24 hrs. The aliquots were passed through 0.45µm membrane flter and analyzed spectrophotometrically at λmax= at 232 nm, E1%1 cm = 16,398. Concentration (C) of various forms was determined using the formula:

C = Absorbance x Dilution factor

E1%1 cm

Results

Virtual analysis from Crystal Structure Prediction (CSP)

The virtual analysis of polymorph screening using Polymorph Predictor module of Biovia Material Studio was carried out starting from molecular structure of metformin (Figure 1).

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 1: Molecular structure of metformin.

The simulation result was retrieved in form of a table that contains data on space groups, lattice energy and lattice constants corresponding to various predicted polymorphs. Out of the various generated structures, 60 unique sets were extracted corresponding based on low energy and high-density criteria (Table 1).

Table 1: CSP results of metformin base.

Characterization

The practically isolated three forms of metformin free base were analysed using sophisticated tools such as DSC, FTIR spectroscopy, PXRD and optical microscopy.

DSC thermograms - The difference in position of melting endotherms of forms I, II and III observed in DSC curves gives the indication of formation of multiple solid forms. The form I isolated from benzaldehyde had shown a sharp endotherm at 134.01°C. The form II obtained from 2-propanol exhibits melting endotherm at 111.24°C. Form III obtained from cyclohexane and toluene shows endothermic event at 79.84°C (Table 2, Figure 2 (a-c)).

Polymorph (solvent used for isolation)

DSC endotherm (°C)

Form I (benzaldehyde)

134.01

Form II (2-propanol)

111.24

Form III (cyclohexane+ toluene)

79.84

Table 2: Melting point (°C) and DSC endotherms (°C) of metformin polymorphs/solvatomorph. 

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 2a: DSC endotherm of form I of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 2b: DSC endotherm of form II of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 2c: DSC endotherm of form III of metformin.

 

FTIR Spectroscopy

Variations in the characteristic spectral frequencies of observed forms further demonstrates the existence of polymorphism in metformin free base. The information obtained from FTIR spectra (Table 3, Figure 3(a-c)) of form I, II and III indicated the differences in the intermolecular interactions within these modifications.

Functional group assignment

FTIR Peaks (cm-1)

Form I

Form II

Form III

N-H primary stretching

3368

3369.21

3370.19

N-H secondary stretching

3181.20

3167.16

3173

C=N stretching

2250

2216

2278

CH2 N-H bending

1589.85

1557.91

1576.68

O-H stretch

-

-

-

O-H bend

-

-

-

C-H asymmetric stretch

-

-

-

Table 3: Prominent peaks of metformin polymorphs in FTIR spectra. 

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 3a: FTIR spectrum of form I of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 3b: FTIR spectrum of form II of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 3c: FTIR spectrum of form III of metformin.

 

PXRD Study

The various peaks observed in PXRD scans (Figure 4) of three forms of metformin are given in table 4. Sharp differences in their 2θ values clearly characterize them as different polymorphic forms.

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 4: PXRD patterns of form I, II and III of metformin.

 

Form I

Form II

Form III

7.98

8.02

-

8.73

8.81

-

9.93

9.92

-

-

11.09

11.8

12.15

12.01

-

12.72

12.57

-

-

13.65

13.95

14.2

14.2

-

15.87

15.78

15.72

16.12

16.08

-

-

16.46

-

-

16.76

16.78

17.2

17

-

17.4

-

-

17.67

-

-

18.38

18.3

18.35

-

18.72

-

19.33

19.26

19.01

19.95

19.92

-

-

20.08

-

20.72

20.65

-

-

21.44

21.26

21.71

21.62

-

22.4

-

-

22.65

-

22.76

22.87

-

-

-

23.01

-

23.82

23.38

23.77

24.2

24.21

-

24.85

-

24.88

25.33

25.29

25.56

-

25.95

-

26.24

26.8

26.29

27.27

-

27.07

28.13

28.10

-

28.39

28.34

-

-

28.59

28.67

-

29.16

-

-

-

29.87

-

30.06

30.01

30.67

-

30.08

31.79

31.24

31.13

32.53

-

32.82

33.01

-

-

33.68

-

-

-

34.44

-

 

 

35.94

 

 

38.48

 

 

40.75

Table 4: Prominent peaks (2θ) observed in PXRD patterns of four forms of metformin. 

 

Crystal structure determination from PXRD patterns

The detailed analysis of crystal structures solved from PXRD patterns by Powder Solve program of MS was attempted and crystallographic parameters of predicted and observed forms are given in table 5.

Polymorph

Form I

Form II

Form III

Solvent used for re-crystallisation

Benzaldehyde

2-Propanol

Cyclohexane+ toluene

Crystal system

triclinic

triclinic

triclinic

Space group

P-1

P-1

P-1

Z

2

2

2

a(Å)

Predt.

12.28

9.71

9.47

Expt.

12.70

11.71

9.37

b (Å)

Predt.

12.66

12.09

8.77

Expt.

12.31

10.29

8.88

c (Å)

Predt.

7.8

9.74

6.43

Expt.

7.97

9560

6.37

α (o)

Predt.

109.86

90.00

95.75

Expt.

110.86

83.91

95.60

β (o)

Predt.

83.84

103.58

89.49

Expt.

83.87

108.64

89.56

γ (o)

Predt.

117.02

90.00

108.91

Expt.

116.44

98.69

108.77

p

(g cm-3)

Predt.

1.34

1.36

1.38

Expt.

1.33

1.36

1.37

Elatt

(kcal mol-1)

Predt.

-148.61

-147.11

-144.89

Expt.

-

-

-

Table 5: Crystallographic data for polymorphs of metformin. 

 

Predt.: predicted parameter; Expt.: experimentally observed parameter

Morphology study

Crystal morphology and habit of the developed forms of metformin was studied using growth morphology algorithm of morphology module of MS starting from their respective crystal structures. It is based upon the hypothesis that the growth rate of a crystal face is proportional to its attachment energy (Eatt). Eatt is a habit controlling factor which is defined as energy per mol of the molecule liberated when a new layer having thickness dhkl (hkl indicates the Miller indices assigning a set of faces that are equivalent by the symmetry of the crystal) is joined to the surface of the crystal). Thus, the crystal faces with lowest attachment energies (in terms of magnitude) are the slowest growing and, considered as morphologically most important facets [36,37]. Now, if the attachment energy of the slowest developing or morphologically important face is taken as an estimate of the growing speed of a crystal, it can easily explain the appearance tendency of the developed forms in lattice energy landscape. This further aids lattice energy model in ranking the polymorphs based on their stability.

Furthermore, notable differences in morphology of the crystals of metformin displayed by optical examination proposes that they may be variant forms. The absence of actual conditions provided during crystallization and the influence of solvent on the growth of the experimental crystal may be the cause of unusual difference between the simulated and the experimental morphology. The results of morphology prediction are shown in table 6 and figures 5-7 represent the crystal habit along with their most developed Morphologically Important (MI) faces of various polymorphs of metformin. The experimental morphologies reported by optical microscopy of these crystal forms are shown in figure 8.

Polymorph

Growth Morphology

Aspect Ratio

MI facets

h k l (multiplicity)

Total % area

(100 X [(total surface area of the facet)/(total surface area)]

Eatt

(kcal/ mol)

 

Form I

2.60

5

100 (2)

39.76

-11.71

 

01-1 (2)

30.34

-15.41

 

010 (2)

24.08

-16.79

 

1-10 (2)

3.76

-23.08

 

02-1 (2)

2.06

-23.61

 

Form II

2.63

4

010 (2)

45.18

-10.96

 

10-1(2)

31.44

-11.15

 

100 (2)

14.07

-12.13

 

001 (2)

9.31

-12.26

 

Form III

3.03

6

1-10 (2)

28.17

-9.90

 

010 (2)

25.62

-14

 

100 (2)

23.66

-26.83

 

101 (2)

9.57

-27.09

 

1-11 (2)

6.95

-26.20

 

001 (2)

6.02

-23.29

 

Table 6: Morphology prediction of isolated forms of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 5: Simulated crystal habit and M.I. facets of observed form I of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 6: Simulated crystal habit and M.I. facets of observed form II of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 7: Simulated crystal habit and M.I. facets of observed form III of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 8: Optical microscopy images showing observed morphologies of three isolated forms of metformin base (at 25 X magnification).

 

Solubility study

The solubility study performed in distilled water at 37°C (Table 7) indicated that the form with highest lattice energy or stability (form III) was least soluble (271 ± 2.4). The solubility profile was thus found in accord with their lattice energy data.

Form

Solubility in distilled water at 37°C (mg/ ml) ± SD

Form I

329 ± 1.2

Form II

307 ± 2.5

Form III

201 ± 3.2

Table 7: Solubility data of observed forms of metformin. 

Discussion

The results of the prediction study compiled in a tabular form revealed the significance of CSP in acquiring the data on possible polymorphs of a drug molecule. The knowledge generated from lattice energy landscape would give an idea of prevalence of multiple solid forms of a drug molecule based on crystal packing space featuring low energy and high-density crystal structures. Polymorph Predictor module and user-friendly algorithms of Biovia MS has shaped CSP as a powerful tool to predict the crystal structures of a drug substance.

The sharp endothermic peaks of observed forms at different positions in DSC curves clearly gives a clue about the existence of different solid form of drug.

The shift in FTIR bands depicting changes in vibrational frequencies support the existence of different solid phases due to variable hydrogen bonding patterns. This technique helps in identifying functional groups involved in hydrogen bonding.

The unique differences in PXRD patterns of three forms has confirmed the prevalence of polymorphism in metformin free base. The marked appearance of new peaks and disappearance of certain prominent peaks supports the evolution of new solid phases.

Crystal structure determination was done from their PXRD patterns due to difficulty in growing single crystals of suitable dimensions. The crystal structure solutions have been successfully attempted by Powder Solve technology of Reflex Plus module of MS software. The form I tends to lie in P-1 space group with triclinic crystal system. It contains two molecules of metformin in a unit cell as indicated in figure 9b facing each other, turned upside down and joined with hydrogen bonds figure 9c. There is dimer formation through intermolecular hydrogen bonds involving N (5)H···N(5) interaction between two molecules. The two dimers are further linked via N (5) H···N (1 interaction. A sheet- like pattern of molecules is observed in 3-D view figure 9d.

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 9: Crystal structure analysis of form I of metformin- (a) Ortep diagram of asymmetric unit with 50% thermal ellipsoid probability (b) Arrangement of molecules in unit cell (c) Hydrogen bonding patterns (d) Molecular packing diagram (3-D network) along a-axis.

 

The crystal form II crystallizes in triclinic crystal system with P-1 space group possessing two molecules of metformin in a unit cell (Figure 10b). The molecules are lying side by side to each other and turned upside down attached through hydrogen bonded dimeric motifs i.e., N (5) H···N (3) (Figure 10c). The dimmers are further connected to each other involving N (4) H···N (4) interaction. The 3-D view indicates linear chains of molecules arranged in a sheet form (Figure 10d).

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 10: Crystal structure analysis of form II of metformin- (a) Ortep diagram of asymmetric unit with 50% thermal ellipsoid probability (b) Arrangement of molecules in unit cell (c) Hydrogen bonding patterns (d) Molecular packing diagram (3-D network) along a-axis.

The crystal form III existing in P-1 space group displays triclinic crystal system possessing two molecules of metformin in a unit cell (Figure 11b). Each molecule is connected to three other molecules arranged in a linear manner w.r.t. each other and turned upside down. Intermolecular dimeric motifs involving N (4) H···N (1) interaction are observed between the molecules (Figure 11c). N (3) H···N (4) interaction is observed between different dimers w.r.t. each other. The 3-D view shows linear chains of molecules with anti-parallel sequence (Figure 11d).

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 11: Crystal structure analysis of form III of metformin- (a) Ortep diagram of asymmetric unit with 50% thermal ellipsoid probability (b) Arrangement of molecules in unit cell (c) Hydrogen bonding patterns (d) Molecular packing diagram (3-D network) along a-axis.

 

The simulated and experimental PXRD scans complement each other as interpreted from Rwp value which further proclaims the neatness of crystal structure determination using powder technology (Figure 12(a-c)). Rwp is a basic measure of similarity between a simulated and an experimental diffraction pattern of each crystal structure and is found out to be below 15%.

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 12a: Rietveld plot form I of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 12b: Rietveld plot form II of metformin.

 

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 12c: Rietveld plot form III of metformin.

 

Structures corresponding to predicted and observed polymorphs of metformin free base found in crystal energy landscape are featured in table 5. The predicted and experimental results are found to be quite complacent with each other. It is clearly seen that developed crystal structures exists in the list of simulated results within an energy difference of 7.5 kcal/mol from the global minima. The simulated crystal structure nos. 6, 11 and 20 complement well with experimentally observed forms. The lattice energy diagram was generated from the predicted structures (Figure 13) depicting colorfully highlighted experimentally matched forms (mentioned under legend)

a-study-showcasing-crystal-medley-of-metformin-free-base-virtual-and-experimental-insights

Figure 13: Lattice energy landscape generated through CSP runs showing experimentally observed three crystal forms of metformin.

 

The interpretation of crystal energy landscape has very well positioned the experimentally observed solid forms of metformin as local minima within an energy difference of approximately 7.0 kcal/mol from the global minimum. This further indicates the existence of multiple metastable forms of the drug.

On interpretation of lattice energy landscape, form III occupies sixth position in the list of predicted structures generated form CSP runs and is nearest to the global minimum. It is high density form having approximately 2.5 kcal/mol higher energy than that of global minimum which further confirms it to be the most stable crystalline form. Form II exists as eleventh local minima in the lattice energy landscape. The relatively low lattice energy and highest density value provided it good stability as compared to other possible forms. Form I is found as the twentieth local minimum predicted in the study.

The morphology prediction has well demonstrated that lattice energy model has ranked the observed crystal forms in correct manner with respect to their stability and observing tendency.

The morphology prediction of various forms of metformin and their ranking in the lattice energy landscape are in good agreement with each other as far as the stability is concerned (Table 1). It was concluded after careful examination that form I is most stable having highest Eatt of its M.I. facet (100), followed by form II (facet (010)), and form III (facet (1-10)). This also expresses the growing speed of crystal and their observing tendency during experimentation.

It is likely to understand that many low energies predicted structures have not assimilated as polymorphs as they may not be favored kinetically and thus may not be appear experimental crystallization temperatures. The higher aspect ratios (>7) can also be the other parameter for not observing these hypothetical low energy forms including the global minimum. Thus, morphology prediction further assists the CSP by filtering out some of the hypothetical structures based on the consideration of growth rates, using the attachment-energy model. The knowledge of aspect ratios indicates that crystals growing as thin plates so slowly that they are unlikely to be found in competition with equally thermodynamically stable structures.

Visual examination by optical microscopy, generates information on the crystal topography and habit suggesting the prevalence of different crystal phases of metformin free base.

Solubility study also demonstrates the existence of multiple forms of the drug.

Conclusion

The findings illustrate the implications of CSP in understanding the concepts of polymorphism in metformin free base. Out of the three isolated forms, form I of metformin free base has been found to be the most stable which can be further considered for development. Thus, the varied options of polymorphic forms with desired characteristics has been provided by lattice energy landscape of drug molecule. The efficiency of experimental work can be facilitated by utilizing a CSP which can reduce the amount of time and costs of the experimental part of research and development. Metformin free base has a strong tendency to exist in variable crystal forms as shown by CSP and illustrated in the crystal energy landscape. Onset of multiple phases of drug molecule is depicted from thermograms and PXRD scans which is also backed by spectral analysis using FTIR. Crystal structure determination from PXRD patterns confirmed the development of three forms of metformin. The variation in solubility values further helps in selection of suitable form for isolation. The study insists in scrutinizing other parameters such as solvent effects on crystallization for more detailed vision on the polymorphic aspects of a drug molecule. The study plays a constructive role in accumulating the structurally diversified data of a drug molecule which further permits to select the desired crystal form for future development.

Conflict of Interests

All authors declare no conflicts of interest in this article.

References

  1. Zhang GZ, Law D, Schmitt EA, Qiu Y (2004) Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Delivery Rev 56: 371-390.
  2. Lee AY, Erdemir D, Myerson AS (2011) Crystal Polymorphism in Chemical Process Development. Annu Rev Chem Biomol Eng 2: 259-280.
  3. Brittain HG (2000) The impact of polymorphism on drug development: a regulatory viewpoint. Am Pharm Rev 3: 67-68.
  4. Grant DJ, Byrn SR (2004) A timely re-examination of drug polymorphism in pharmaceutical development and regulation. Adv Drug Deliv Rev 56: 237-239.
  5. Haleblian J, McCrone W (1969) Pharmaceutical applications of polymorphism. J Pharm Sci 58: 911-929.
  6. Pinnamaneni S, Das NG, Das SK (2002) Formulation approaches for orally administered poorly soluble drugs. Pharmazie 54: 291-300.
  7. Bernstein J (2002) Polymorphism in Molecular Crystals. Clarendon Press, Oxford, UK.            
  8. Brittain HG, Grant DJW (1999) Effect of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain HG (ed.). Polymorphism in Pharmaceutical Solids. Marcel Dekker Inc., New York, USA. Pg no: 279-330.
  9. Borka L, Halebian J (1991) Crystal polymorphism of pharmaceuticals. Acta Pharm Jugosl 40: 71-94.   
  10. Bernstein J (2008) Crystal polymorphism. In: Novoa JJ, Dario B, Lia A (eds.). Engineering of crystalline material properties. Springer, The Netherlands. Pg no: 87-109.
  11. Thayer AM (2007) The choice of pharmaceutical crystalline form can be used to optimize drug properties, and co-crystals are emerging as new alternatives. Form and Function 85: 17-30.
  12. Miller JM, Collman BM, Greene LR, Grant DJ, Blackburn AC (2005) Identifying the stable polymorphs early in the drug discovery development process. Pharm Dev Technology 10: 291-297.
  13. Palmer SC, Strippoli GF (2018) Metformin as first-line treatment for type 2 diabetes. The Lancet 392: 120.
  14. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, et al. (2011) Gerosuppressant metformin: less is more. Aging (Albany NY) 3: 348-362.
  15. Moiseeva O, Deschênes-Simard X, St-Germain E, Igelmann S, Huot G, et al. (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κ B activation. Aging cell 12: 489-498.
  16. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, et al. (2011) If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 3: 148-157.
  17. Pryor R, Cabreiro F (2015) Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J 471: 307-322.
  18. Williams HD, Ford L, Lim S, Han S, Baumann J, et al. (2018) Transformation of biopharmaceutical classification system class I and III drugs into ionic liquids and lipophilic salts for enhanced developability using lipid formulations. J Pharm Sci 107: 203-216.
  19. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, et al. (2007) Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur J Pharm Biopharm 67: 196-201.
  20. Wen H, Jung H, Li X (2015) Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J 17: 1327-1340.
  21. Tinworth KD, Boston RC, Harris PA, Sillence MN, Raidal SL, et al. (2012) The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. Vet J 191: 79-84.
  22. Pernicova I, Korbonits M (2014) Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10: 143.
  23. Pein M, Preis M, Eckert C, Kiene FE (2014) Taste-masking assessment of solid oral dosage forms-a critical review. Int J Pharm 465: 239-254.
  24. García-Pérez LE, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D (2013) Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 4: 175-194.
  25. Timmins P, Winter WJ, Srivastava SK, Bretnall AE, Wei C, Powers GL, inventors; Bristol-Myers Squibb Co, assignee. Salts of metformin and method. United States patent US 6,031,004. 2000 Feb 29.
  26. Kim SW, Jun SS, Jo YG, Koo JS, Kim YW, Kim BH, Kim D, inventors; Hanall Pharmaceutical Co Ltd, assignee. N, N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same. United States patent US 8,076,377. 2011 Dec 13.
  27. Allen FH, Motherwell WD (2002) Applications of the Cambridge Structural Database in organic chemistry and crystal chemistry. Acta Crystallog B 58: 407-422.
  28. Beyer T, Lewis T, Price SL (2001) Which organic crystal structures are predictable by Lattice energy minimisation? Cryst Eng Comm 3: 178-212.
  29. Price SL (2008) From crystal structure prediction to polymorph prediction: interpreting the crystal energy landscape. Phys Chem Chem Phys 10: 1996-2009.
  30. Bardwell DA, Adjiman CS, Arnautova YA, Bartashevich E, Boerrigter SX, et al. (2011) Towards crystal structure prediction of complex organic compounds - a report on the fifth blind test. Acta Crystallogr B 67: 535-551.
  31. Young RA (1993) The Rietveld method. In: Young RA (ed.). IUCr Monographs on Crystallography no 5, Oxford University Press, New York, USA.
  32. Jinjin Li, Yuriy A, Abramov, Doherty MF (2017) New Tricks of the Trade for Crystal Structure Refinement. ACS Cent Sci 3: 726-733.
  33. Fengyun CGW (2013) Molecular Simulation and Prediction of RDX Crystal Morphology. Energ Mater 5: 583-588.
  34. Rohl AL (2003) Computer prediction of crystal morphology. Curr Opin Solid St M 7: 21-26.
  35. Docherty R, Clydesdale G, Roberts KJ, Bennema P (1991) Application of Bravais-Friedel- Donnay-Harker, attachment energy and Ising models to predicting and understanding the morphology of molecular crystals. J Phys D: Appl Phys 24: 89-99.
  36. Prywer J (2002) Morphological importance of crystal faces in connection with growth rates and crystallographic structure of crystal. Cryst Growth Des 2: 281-286.
  37. Prywer J (2001) Effect of crystal geometry on disappearance of slow-growing faces. J Cryst Growth 224: 134-44.
Ocimum Scientific Publishers

This work is licensed under a Creative Commons Attribution 4.0 International License.  Creative Commons License

Copyright © 2019 - All Rights Reserved - ocimumpublishers.com